Loading
A phase 3 trial testing Darovasertib in uveal melanoma, now recruiting.
Neoadjuvant Darovasertib in Primary Uveal Melanoma is a phase 3 interventional study registered as NCT07015190, led by IDEAYA Biosciences, and recruiting on the registry. Official title: A Randomised, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10). Planned enrolment is 520 participants (estimated). The study started in 2026-01-25 and primary completion is expected in 2030-10. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, Uveal melanoma.
Shares Darovasertib, Uveal melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/